16 results about "Antiviral therapy" patented technology

The invention relates to an application of SLC15A3 in preparation of an anti-dengue virus drug, and discovers that a novel antiviral protein SLC15A3 has a novel application of efficiently targeting a dengue virus non-structural protein NS4A so as to inhibit the proliferation of a dengue virus in a host cell. The invention develops a new field of clinical application of the humanized antiviral protein in the field of antiviral prevention and treatment, so that a new thought and direction are provided for drug development of targeted dengue virus non-structural protein NS4A, a scientific basis is provided for development of anti-dengue virus drugs, and a new thought is provided for clinical antiviral treatment.

The invention provides an mRNA molecule of IFN-omega, a recombinant expression vector, lipid nanoparticles and application, the mRNA molecule of IFN-omega comprises an ORF sequence for coding IFN-omega protein, and the nucleotide sequence of the ORF sequence is as shown in SEQ ID NO: 7. The invention develops a novel antiviral treatment scheme for expressing IFN-omega in vivo by using mRNA-LNP, so that the treatment effect of resisting FCV and FHV-1 is improved, the bioavailability is improved, the safety risk is reduced, and the application has important clinical significance and application value.

Formulas for use in enhancing the transduction efficiency of lentiviral vector (LV) particles into various target cells are disclosed herein. For example, a formulation for use in enhancing the transduction of paramyxovirus pseudotype lentiviral vector particles into target cells may comprise a cell-permeable peptide (CPP) comprising at least one of Vectofusion-1 or LAH4-C; and poloxamer 407, wherein the concentration of poloxamer 407 is greater than or equal to the concentration of CPP. Additionally, a method of using such formulations to enhance the transduction of LV particles, including particularly in vivo transduction, is disclosed herein.

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3)), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to application of an NtSGRL1-related biological product in tobacco antivirus, and the nucleotide sequence of the NtSGRL1 is shown as SEQ ID NO.1. The invention also relates to an application of the NtSGRL1-related biological product in tobacco antivirus. According to the invention, a CRISPR-Cas9 mediated common tobacco NtSGRL1 knockout strain Ntsgrl1 is created through genetic transformation, and four main tobacco viruses of tomato yellow leaf curl virus, tobacco mosaic virus, potato Y virus and tomato spotted wilt virus are respectively adopted to inoculate the obtained Ntsgrl1 function deletion mutant strain. Disease resistance identification results show that compared with wild and overexpression strains, the Ntsgrl1 mutant strain shows broad-spectrum and significantly enhanced resistance to four tested viruses, which is specifically embodied in that the system symptom development is significantly inhibited, and the virus accumulation in the plant is significantly reduced.

The application discloses a kind of based on CLDN1 protein's derivative peptide, fusion protein and its application, the derivative peptide includes the amino acid sequence as shown in SEQ ID NO:3, the amino acid sequence of the fusion protein is as shown in SEQ ID NO:2.The application finds that several derivative peptides containing CLDN1 protein extracellular loop EL1 peptide segment have significant inhibitory effect on various RNA and DNA envelope viruses.The fusion protein shows significant in vivo antiviral activity, can alleviate lung inflammation caused by RSV infection, and reduce viral nucleic acid level.Therefore, the derivative peptide and fusion protein based on CLDN1 protein designed in the application can be used for antiviral therapy or prophylactic drug research and development, and have wide application prospect.

The present invention provides compositions and methods for treating HPV infections, including pre-malignant and cancerous infections. Compounds that specifically bind to and inactivate the HPV E6 protein are disclosed.

Compounds, methods, and compositions for treating or preventing viral infections using nucleoside compounds. The nucleoside compounds have increased antiviral activity potential with the result of inhibiting at least one of flaviviruses, herpesviruses, polyomaviruses, alphaviruses, enteroviruses, filoviruses matonaviruses, phenuiviruses, Hepatitis B virus, and / or coronaviruses.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating chronic hepatitis cirrhosis and hepatic fibrosis, a traditional Chinese medicine compound preparation and application. On the basis of combined antiviral treatment, the traditional Chinese medicine compound preparation can remarkably improve symptoms such as hypochondriac discomfort, hypodynamia and poor appetite of a patient, reduce serological indexes (such as HA and LN) of hepatic fibrosis, improve the liver hardness number (LSM) and effectively delay and even partially reverse the hepatic fibrosis process, and the unique advantage of combined treatment of traditional Chinese medicine and western medicine is shown. The traditional Chinese medicine compound preparation is rigorous in formula and clear in principle, and has remarkable clinical applicability and popularization and application value. The traditional Chinese medicine composition is developed into fixed dosage forms such as a mixture, so that standardization and normalization of traditional Chinese medicine treatment of hepatic fibrosis are promoted, and the traditional Chinese medicine composition has good social and economic benefits.

The invention provides an event-driven antiviral treatment service state processing method and system, and belongs to the technical field of medical service management.The method comprises the steps that firstly, event trigger signals of all nodes of an antiviral treatment service are collected, and the event trigger signals comprise treatment operation, patient states and treatment resource associated information; judging an event influence level according to associated information carried by the event trigger signal, and determining an influence type; determining a target state in combination with the current business operation state and guiding transition, and generating a business state transition result; on the basis of the business state transition result, linkage of each treatment business node is carried out to generate adaptive treatment business response content, and a treatment business collaborative response scheme is formed through integration; transmitting a treatment service collaborative response scheme and collecting service execution result data; and according to the service execution result data, the judgment basis and the state corresponding relation are adjusted to form a dynamic optimization link, so that the service change can be sensed and processed in real time, the service state is dynamically optimized, and the treatment efficiency and accuracy are improved.

The invention belongs to the field of medical research, and particularly relates to a method, system and device for evaluating HIV antiviral therapy compliance and a storage medium. The method comprises the following steps: acquiring index data for reflecting ART compliance of an HIV infected person, wherein the index data comprises a nursing retention state, a drug holding rate and a CD4 cell count; constructing a group trajectory model GBTM, and identifying trajectory subgroups of different antiviral treatment compliance in the HIV infected person based on the index data; utilizing a Logistic regression model to evaluate the influence of the demology and ART variable level of different HIV infected persons on the affiliation probability of each trajectory subgroup; utilizing a Cox proportional risk model to evaluate the association between each track subgroup and all-factor death, AIDS death and non-AIDS death; and finally, constructing a dynamic prediction model based on the nursing retention, the drug coverage rate and the CD4 cell counting data by using the combined model, so as to realize real-time early warning of the death risk.

Methods and compositions for diagnosing, preventing or treating a viral infection in a subject comprising administering to a subject in need thereof an effective amount of a glycosidase or a sulfatase to degrade a glycan, such as heparan sulfate, to inhibit viral infection, such as COVID-19. Methods for identifying a glycosidase, a sulfatase, or a microbe associated with increased susceptibility to viral infection in a subject.

Disclosed are delivery and expression systems of multiple antiviral therapeutic molecules. The therapeutic molecules include a novel class of dual-functional peptide and defective interfering genes of a virus. Also disclosed are compositions comprising the therapeutic molecules that are useful for the treatment and prevention of viral infections. Also disclosed herein are the method of making and using a vector that expresses the therapeutic molecules. Therapeutic molecules include cellular components such as RNA, DNA, peptide, proteins or combination thereof.

A method of treating a viral disease associated with targeting of PDZ domain proteins by a viral disease-inducing virus, in a subject in need of such therapy, comprising administering to the subject an inhibitor of at least one of 20s proteasome subunit β6 (Prosβ6), 20s proteasome subunit β2 (Prosβ2), and β-Transducin repeat-containing protein (βTrCP), thereby causing the death of cells that have been infected by the viral disease-inducing virus. The viral disease-inducing virus may be, for example, HPV, Adenovirus, Influenza A, HTLV-1, HIV, West Nile, Dengue, or SARS-CoV. Hie HPV may be a high-risk HPV strain such as HPV strain 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68. The viral disease may be an HPV-induced cancer.

This invention belongs to the field of virology, specifically relating to a chimeric VSV recombinant virus and its applications; specifically, it discloses a chimeric VSV recombinant virus strain co-expressing NiV G and F proteins, wherein the chimeric VSV recombinant virus strain is rVSV△G / NiVMYGF and rVSV△G / NiVBDGF; based on its complete viral structure, higher immunogenicity and better safety, it can serve as an important viral reserve resource for the effective prevention and control, diagnosis and detection, vaccine preparation and antiviral treatment products of Nipah disease in the future.

Compositions of nucleases in formulations with dendrimers are used in pharmaceutically effective dosages as therapeutics for covid-19 and a broad spectrum of viruses in various embodiments. When cationized nucleases are mixed and / or complexed with a dendrimer, an unexpected positive dendrimer effect is manifest. This positive dendrimer effect is shown to be highly effective for catalyzing anti-viral RNase properties. In various embodiments compositions of cationized nucleases in combination with a dendrimer demonstrated this synergistic amplification of anti-viral effectiveness and are used in pharmaceutically effective dosages as therapeutics against covid-19 and a broad spectrum of viruses. An exemplar formulation which exhibits a positive dendrimer effect is cationized RNase A mixed and / or complexed with gen 2 PAMAM dendrimer.